TDOC
TDOC
Teladoc Health, Inc.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $613.85M ▼ | $372.76M ▼ | $-63.84M ▼ | -10.4% ▼ | $-0.36 ▼ | $38.71M ▼ |
| Q4-2025 | $642.27M ▲ | $481.22M ▼ | $-25.14M ▲ | -3.91% ▲ | $-0.14 ▲ | $51.11M ▲ |
| Q3-2025 | $626.44M ▼ | $491.22M ▼ | $-49.51M ▼ | -7.9% ▼ | $-0.28 ▼ | $-35.18M ▼ |
| Q2-2025 | $631.9M ▲ | $495.75M ▼ | $-32.66M ▲ | -5.17% ▲ | $-0.19 ▲ | $2.67M ▲ |
| Q1-2025 | $629.37M | $553.15M | $-93.01M | -14.78% | $-0.53 | $-8.96M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $750.74M ▼ | $2.81B ▼ | $1.47B ▼ | $1.34B ▼ |
| Q4-2025 | $781.08M ▲ | $3.1B ▲ | $1.72B ▲ | $1.39B ▼ |
| Q3-2025 | $726.25M ▲ | $2.88B ▼ | $1.49B ▲ | $1.39B ▼ |
| Q2-2025 | $679.62M ▼ | $2.89B ▼ | $1.47B ▼ | $1.42B ▼ |
| Q1-2025 | $1.19B | $3.44B | $2.02B | $1.43B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-63.84M ▼ | $9.52M ▼ | $-36.52M ▼ | $-2.45M ▼ | $-30.35M ▼ | $7.86M ▼ |
| Q4-2025 | $-25.14M ▲ | $87.74M ▼ | $-34.32M ▲ | $1.1M ▲ | $54.84M ▲ | $85.12M ▲ |
| Q3-2025 | $-49.51M ▼ | $99.26M ▲ | $-48.72M ▲ | $-3.59M ▲ | $46.63M ▲ | $67.95M ▼ |
| Q2-2025 | $-32.66M ▲ | $91.43M ▲ | $-59.7M ▲ | $-549.93M ▼ | $-513.71M ▼ | $90.16M ▲ |
| Q1-2025 | $-93.01M | $15.92M | $-123.27M | $769K | $-105M | $-15.67M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 | Q1-2026 |
|---|---|---|---|---|
Other | $100.00M ▲ | $110.00M ▲ | $110.00M ▲ | $130.00M ▲ |
Revenue by Geography
| Region | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 |
|---|---|---|---|---|
NonUS | $110.00M ▲ | $120.00M ▲ | $120.00M ▲ | $120.00M ▲ |
UNITED STATES | $520.00M ▲ | $510.00M ▼ | $520.00M ▲ | $490.00M ▼ |
Q1 2026 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Teladoc Health, Inc.'s financial evolution and strategic trajectory over the past five years.
Teladoc combines a sizable revenue base, strong gross margins, and solid free cash flow with a leading position in virtual care. Its balance sheet shows good liquidity and manageable leverage, giving it time and flexibility to refine its business model. The integrated Prism platform, large provider network, and rich data assets provide a strong foundation for differentiated offerings such as chronic care management, primary care, and mental health. Continued investment in AI and platform innovation positions the company to benefit from the long‑term shift toward digital and remote healthcare.
Key risks center on persistent unprofitability, high operating expenses, and significant accumulated losses. A large share of assets are intangible and tied to past acquisitions, creating potential for future impairments if segments underperform. Competitive pressures from big tech, health systems, and specialized digital health startups could squeeze pricing and limit growth in certain lines of business. Regulatory and reimbursement uncertainty in telehealth adds further complexity. Internally, the performance and strategic direction of segments like BetterHelp remain important swing factors for both perception and financial results.
The overall outlook is mixed but still opportunity‑rich. On one hand, Teladoc operates in a growing market with structural tailwinds as healthcare delivery becomes more digital, and it has the scale, technology, and cash generation to remain a central player. On the other hand, it must prove that its integrated, whole‑person care model can support sustainable profitability and justify past acquisition spending. Future progress will likely be judged on the company’s ability to improve operating leverage, maintain its innovation edge, and demonstrate clear value to employers, health plans, and patients in a crowded and evolving competitive landscape.
About Teladoc Health, Inc.
https://www.teladochealth.comTeladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $613.85M ▼ | $372.76M ▼ | $-63.84M ▼ | -10.4% ▼ | $-0.36 ▼ | $38.71M ▼ |
| Q4-2025 | $642.27M ▲ | $481.22M ▼ | $-25.14M ▲ | -3.91% ▲ | $-0.14 ▲ | $51.11M ▲ |
| Q3-2025 | $626.44M ▼ | $491.22M ▼ | $-49.51M ▼ | -7.9% ▼ | $-0.28 ▼ | $-35.18M ▼ |
| Q2-2025 | $631.9M ▲ | $495.75M ▼ | $-32.66M ▲ | -5.17% ▲ | $-0.19 ▲ | $2.67M ▲ |
| Q1-2025 | $629.37M | $553.15M | $-93.01M | -14.78% | $-0.53 | $-8.96M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $750.74M ▼ | $2.81B ▼ | $1.47B ▼ | $1.34B ▼ |
| Q4-2025 | $781.08M ▲ | $3.1B ▲ | $1.72B ▲ | $1.39B ▼ |
| Q3-2025 | $726.25M ▲ | $2.88B ▼ | $1.49B ▲ | $1.39B ▼ |
| Q2-2025 | $679.62M ▼ | $2.89B ▼ | $1.47B ▼ | $1.42B ▼ |
| Q1-2025 | $1.19B | $3.44B | $2.02B | $1.43B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-63.84M ▼ | $9.52M ▼ | $-36.52M ▼ | $-2.45M ▼ | $-30.35M ▼ | $7.86M ▼ |
| Q4-2025 | $-25.14M ▲ | $87.74M ▼ | $-34.32M ▲ | $1.1M ▲ | $54.84M ▲ | $85.12M ▲ |
| Q3-2025 | $-49.51M ▼ | $99.26M ▲ | $-48.72M ▲ | $-3.59M ▲ | $46.63M ▲ | $67.95M ▼ |
| Q2-2025 | $-32.66M ▲ | $91.43M ▲ | $-59.7M ▲ | $-549.93M ▼ | $-513.71M ▼ | $90.16M ▲ |
| Q1-2025 | $-93.01M | $15.92M | $-123.27M | $769K | $-105M | $-15.67M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 | Q1-2026 |
|---|---|---|---|---|
Other | $100.00M ▲ | $110.00M ▲ | $110.00M ▲ | $130.00M ▲ |
Revenue by Geography
| Region | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 |
|---|---|---|---|---|
NonUS | $110.00M ▲ | $120.00M ▲ | $120.00M ▲ | $120.00M ▲ |
UNITED STATES | $520.00M ▲ | $510.00M ▼ | $520.00M ▲ | $490.00M ▼ |
Q1 2026 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Teladoc Health, Inc.'s financial evolution and strategic trajectory over the past five years.
Teladoc combines a sizable revenue base, strong gross margins, and solid free cash flow with a leading position in virtual care. Its balance sheet shows good liquidity and manageable leverage, giving it time and flexibility to refine its business model. The integrated Prism platform, large provider network, and rich data assets provide a strong foundation for differentiated offerings such as chronic care management, primary care, and mental health. Continued investment in AI and platform innovation positions the company to benefit from the long‑term shift toward digital and remote healthcare.
Key risks center on persistent unprofitability, high operating expenses, and significant accumulated losses. A large share of assets are intangible and tied to past acquisitions, creating potential for future impairments if segments underperform. Competitive pressures from big tech, health systems, and specialized digital health startups could squeeze pricing and limit growth in certain lines of business. Regulatory and reimbursement uncertainty in telehealth adds further complexity. Internally, the performance and strategic direction of segments like BetterHelp remain important swing factors for both perception and financial results.
The overall outlook is mixed but still opportunity‑rich. On one hand, Teladoc operates in a growing market with structural tailwinds as healthcare delivery becomes more digital, and it has the scale, technology, and cash generation to remain a central player. On the other hand, it must prove that its integrated, whole‑person care model can support sustainable profitability and justify past acquisition spending. Future progress will likely be judged on the company’s ability to improve operating leverage, maintain its innovation edge, and demonstrate clear value to employers, health plans, and patients in a crowded and evolving competitive landscape.

CEO
Charles Divita
Compensation Summary
(Year 2025)
Upcoming Earnings
ETFs Holding This Stock
Summary
Showing Top 3 of 160
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
B of A Securities
Buy
Citigroup
Neutral
Evercore ISI Group
In Line
Barclays
Equal Weight
JP Morgan
Neutral
Deutsche Bank
Buy
Grade Summary
Showing Top 6 of 14
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:21.91M
Value:$212.97M
BLACKROCK INC.
Shares:21.61M
Value:$210.06M
BLACKROCK, INC.
Shares:14.61M
Value:$142.04M
Summary
Showing Top 3 of 587

